

## Regimen Reference Order – GENU – olaparib

ARIA: GENU - [olaparib]

**Planned Course:** Twice daily until disease progression or unacceptable toxicity  
(1 cycle = 30 days)

**Indication for Use:** BRCA or ATM Mutated Castration-Resistant Prostate Cancer

**Proceed with treatment if:**

**ANC equal to or greater than  $1.5 \times 10^9/L$  AND Platelets equal to or greater than  $100 \times 10^9/L$**

❖ **Contact Physician if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Treatment Regimen – GENU – olaparib

Drug	Dose	CCMB Administration Guideline
olaparib	300 mg	Orally twice daily with or without food Swallow whole (Self-administered at home)
<b>Tablet formulation: olaparib (Lynparza®) available dosage strengths: 100 mg, 150 mg tablets</b> <b>Classification: Cytotoxic, Hazardous</b>		

### REQUIRED MONITORING

All Cycles

- CBC and biochemistry as per Physician Orders

#### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

### INSTRUCTIONS FOR PATIENT

- Instruct patient to continue taking anti-emetic(s) at home
- olaparib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on olaparib

### ADDITIONAL INFORMATION

- olaparib can rarely cause pneumonitis
- secondary malignancy (MDS/AML) has been reported with olaparib (rare). Monitor for prolonged cytopenia
- LHRH analog treatment (i.e. leuprolide or goserelin) or LHRH antagonist (degarelix) is continued during olaparib treatment
- olaparib will be dispensed by CCMB Pharmacy